Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,229 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
Pieske B, Tschöpe C, de Boer RA, Fraser AG, Anker SD, Donal E, Edelmann F, Fu M, Guazzi M, Lam CSP, Lancellotti P, Melenovsky V, Morris DA, Nagel E, Pieske-Kraigher E, Ponikowski P, Solomon SD, Vasan RS, Rutten FH, Voors AA, Ruschitzka F, Paulus WJ, Seferovic P, Filippatos G. Pieske B, et al. Among authors: solomon sd. Eur Heart J. 2019 Oct 21;40(40):3297-3317. doi: 10.1093/eurheartj/ehz641. Eur Heart J. 2019. PMID: 31504452 Free article.
Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study.
Solomon SD, Skali H, Bourgoun M, Fang J, Ghali JK, Martelet M, Wojciechowski D, Ansmite B, Skards J, Laks T, Henry D, Packer M, Pfeffer MA; OVERTURE Investigators. Solomon SD, et al. Am Heart J. 2005 Aug;150(2):257-62. doi: 10.1016/j.ahj.2004.09.056. Am Heart J. 2005. PMID: 16086927 Clinical Trial.
Prognostic use of echocardiography 1 year after a myocardial infarction.
Skali H, Zornoff LA, Pfeffer MA, Arnold MO, Lamas GA, Moyé LA, Plappert T, Rouleau JL, Sussex BA, St John Sutton M, Braunwald E, Solomon SD; Survival and Ventricular Enlargement (SAVE) Investigators. Skali H, et al. Among authors: solomon sd. Am Heart J. 2005 Oct;150(4):743-9. doi: 10.1016/j.ahj.2004.10.033. Am Heart J. 2005. PMID: 16209977
Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
Janardhanan R, Kenchaiah S, Velazquez EJ, Park Y, McMurray JJ, Weaver WD, Finn PV, White HD, Marin-Neto JA, O'Connor C, Pfeffer MA, Califf RM, Solomon SD; VALIANT Investigators. Janardhanan R, et al. Among authors: solomon sd. Am Heart J. 2006 Jul;152(1):183-9. doi: 10.1016/j.ahj.2005.11.013. Am Heart J. 2006. PMID: 16824854
Mitral regurgitation in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: prognostic significance and relation to ventricular size and function.
Amigoni M, Meris A, Thune JJ, Mangalat D, Skali H, Bourgoun M, Warnica JW, Barvik S, Arnold JM, Velazquez EJ, Van de Werf F, Ghali J, McMurray JJ, Køber L, Pfeffer MA, Solomon SD. Amigoni M, et al. Among authors: solomon sd. Eur Heart J. 2007 Feb;28(3):326-33. doi: 10.1093/eurheartj/ehl464. Epub 2007 Jan 24. Eur Heart J. 2007. PMID: 17251259
Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study.
Lewis EF, Velazquez EJ, Solomon SD, Hellkamp AS, McMurray JJ, Mathias J, Rouleau JL, Maggioni AP, Swedberg K, Kober L, White H, Dalby AJ, Francis GS, Zannad F, Califf RM, Pfeffer MA. Lewis EF, et al. Among authors: solomon sd. Eur Heart J. 2008 Mar;29(6):748-56. doi: 10.1093/eurheartj/ehn062. Epub 2008 Feb 28. Eur Heart J. 2008. PMID: 18308687 Clinical Trial.
Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, Solomon SD, Granger CB, Swedberg K, Yusuf S, Pfeffer MA, McMurray JJ; CHARM Investigators. MacDonald MR, et al. Among authors: solomon sd. Eur Heart J. 2008 Jun;29(11):1377-85. doi: 10.1093/eurheartj/ehn153. Epub 2008 Apr 14. Eur Heart J. 2008. PMID: 18413309 Clinical Trial.
Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.
Pocock SJ, McMurray JJ, Dobson J, Yusuf S, Granger CB, Michelson EL, Ostergren J, Pfeffer MA, Solomon SD, Anker SD, Swedberg KB. Pocock SJ, et al. Among authors: solomon sd. Eur Heart J. 2008 Nov;29(21):2641-50. doi: 10.1093/eurheartj/ehn420. Epub 2008 Sep 26. Eur Heart J. 2008. PMID: 18819960 Clinical Trial.
1,229 results